Dr. Rita Sanghvi S. Mehta, MD

Dr. Mehta practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Mehta's NPI, 1215017470, was assigned on October 16, 2006. Dr. Mehta graduated from M.G.M. Medical College in 1982. Dr. Mehta holds California license 000000A50798.

Dr. Mehta's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Mehta's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians. Dmand AI also links Dr. Mehta to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mehta practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mehta's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Mehta is board certified in board certified in oncology by the Board Certification. Dr. Mehta is licensed in California.

Dmand AI lists menopause, osteoporosis and UTI among the conditions Dr. Mehta treats.

CMS data shows 390 Medicare services from Dr. Mehta across 5 procedure codes in 2024, for 168 Medicare patients. Medicare paid $33,789 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 168 Medicare patients who saw Dr. Mehta in 2024. The largest group is 65 to 74, with 91 patients. 75% of them have cancer, and 75% have high cholesterol. 39% are also on Medicaid. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mehta's median patient age at 64, with 97% women.

In 2024, Dr. Mehta wrote 442 Medicare Part D claims for 98 patients. 85% of them were for generic drugs. CMS names the drug for 312 of them, across 8 drugs with 11 or more claims each, at $611,511 in total drug cost. In 2023, CMS named 326 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Mehta for performance year 2024, reported through an alternative payment model (APM). Dr. Mehta accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mehta as offering telehealth.

Dmand AI links 29 papers to Dr. Mehta, published from 2008 to 2011. The most frequent topics are Breast Neoplasms, Biomarkers, Tumor and Antineoplastic Combined Chemotherapy Protocols. Dr. Mehta has published most often in Breast Cancer Res Treat. Dr. Mehta's most frequent co-authors are John P P. Fruehauf, MD, Tauseef F. Ahmed, MD and Eric J. Feldman, MD.

Dmand AI links Dr. Mehta to 10 clinical trials, 5 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Carcinoma In Situ and Breast Diseases. University of California, Irvine sponsors the most, 4.

CMS Open Payments shows 17 general payments to Dr. Mehta from 4 drug and device companies from 2017 to 2024. Consulting fees make up the largest share, 93% of the total. Novartis Pharmaceuticals Corporation paid the most, $15,873.

Dmand AI lists 6 awards for Dr. Mehta, most recently Top Doctor in 2019. Dr. Mehta serves on SWOG Breast translational Committee and Breast committee and Member Breast working group SWOG.

Dr. Mehta graduated from M.G.M. Medical College in 1982. Dr. Mehta is a member of ASCO.

Dr. Mehta is in network with 13 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.